Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 20,000 Shares

Key Points

• Jula Inrig sold 20,000 shares of Travere on May 4 at an average $45 (≈$900,000) under a pre‑arranged Rule 10b5‑1 plan to cover tax withholding from vested awards, cutting her stake by 15.21% to 111,473 shares; she also executed several smaller sales in mid‑April and early May.
• Travere beat Q1 EPS estimates ($0.05 vs. -$0.24) with revenue up 55.6% YoY to $127.2M (slightly under consensus), and multiple analysts have since raised price targets, leaving a consensus rating of "Moderate Buy" with a target near $47.83.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 20,000 shares of the company's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $45.00, for a total value of $900,000.00. Following the transaction, the insider directly owned 111,473 shares in the company, valued at $5,016,285. The trade was a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Wednesday, May 6th, Jula Inrig sold 311 shares of Travere Therapeutics stock. The shares were sold at an average price of $43.95, for a total value of $13,668.45.
• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The shares were sold at an average price of $46.65, for a total value of $101,417.10.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Stock Down 0.2%

NASDAQ TVTX traded down $0.10 on Wednesday, reaching $44.70. The stock had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The business has a 50 day moving average price of $32.59 and a 200 day moving average price of $32.83. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 1 year low of $13.88 and a 1 year high of $48.61. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. The business's quarterly revenue was up 55.6% compared to the same quarter last year. On average, analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Trading of Travere Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. State of Wyoming bought a new stake in Travere Therapeutics during the 4th quarter valued at approximately $37,000. Torren Management LLC bought a new stake in Travere Therapeutics during the 4th quarter valued at approximately $38,000. Comerica Bank boosted its stake in Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company's stock valued at $43,000 after purchasing an additional 492 shares during the period. Fifth Third Bancorp bought a new stake in Travere Therapeutics during the 1st quarter valued at approximately $35,000. Finally, Smartleaf Asset Management LLC boosted its stake in Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company's stock valued at $45,000 after purchasing an additional 487 shares during the period.

Analyst Ratings Changes

A number of research analysts have commented on the company. Citigroup boosted their target price on Travere Therapeutics from $53.00 to $59.00 and gave the company a "buy" rating in a research note on Tuesday. Wedbush boosted their target price on Travere Therapeutics from $53.00 to $55.00 and gave the company an "outperform" rating in a research note on Tuesday. Wall Street Zen downgraded Travere Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 21st. Canaccord Genuity Group upped their price target on Travere Therapeutics from $47.00 to $56.00 and gave the stock a "buy" rating in a research note on Tuesday, April 14th. Finally, Guggenheim upped their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a "buy" rating in a research note on Friday, April 24th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.83.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a "buy" rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an "overweight" rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a "Buy" and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

About Travere Therapeutics

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.